Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

14.30 +0.50 (+3.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
The Latest Analyst Ratings for Intellia Therapeutics
Via Benzinga
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
3 Mid-Caps That Could Double in 2023
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months. 
Via MarketBeat
7 ‘Next Big Things’ for Investors to Buy for 2023
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown. 
Via InvestorPlace
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
Analyst Ratings for Intellia Therapeutics
Via Benzinga
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
Via Benzinga
Recap: Intellia Therapeutics Q3 Earnings
Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
NTLA Stock Falls as Intellia Therapeutics Announces Public Offering
Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares. 
Via InvestorPlace
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
Earnings Preview For Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
7 Analysts Have This to Say About Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
3 Cathie Wood Stocks to Buy and Hold for 10 Years
The risks are formidable, but the chances of a massive gain are too much to pass up. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
5 Top Stocks Cathie Wood Is Buying Right Now
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies. 
Via InvestorPlace
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading. 
Via Benzinga
Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today?
Applied Optoelectronics (AAOI) stock is climbing higher on Friday after the company revealed a $150 million asset sale and new brand launch. 
Via InvestorPlace
Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
Esports Entertainment (GMBL) stock is falling hard on Friday after the company revealed the pricing of a public stock offering. 
Via InvestorPlace
What Is Going on With Intellia Therapeutics (NTLA) Stock Today?
Intellia Therapeutics (NTLA) stock is on the move Friday after releasing positive clinical trial data for two of its drugs. 
Via InvestorPlace
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.